牛牛AI助理已提取核心訊息
On February 27, 2024, 60 Degrees Pharmaceuticals, Inc. received notification from Nasdaq Listing Qualifications Staff that the company's common stock had not met the minimum closing bid price of $1.00 per share over a 31 consecutive business day period from January 11, 2024, to February 27, 2024. This failure to comply with the Bid Price Rule puts the company at risk of being delisted from The Nasdaq Capital Market. The company has been granted an initial 180-day compliance period, ending on August 26, 2024, to rectify the bid price deficiency. If compliance is not achieved by this deadline, 60 Degrees Pharmaceuticals may be eligible for an additional 180-day period, provided it meets certain conditions, including a potential reverse stock split. The company's common stock and warrants will continue to trade on The Nasdaq under the symbols 'SXTP' and 'SXTPW' while it evaluates options to regain compliance. There is no certainty that the company will be able to meet the Nasdaq's continued listing requirements in the future.
On February 27, 2024, 60 Degrees Pharmaceuticals, Inc. received notification from Nasdaq Listing Qualifications Staff that the company's common stock had not met the minimum closing bid price of $1.00 per share over a 31 consecutive business day period from January 11, 2024, to February 27, 2024. This failure to comply with the Bid Price Rule puts the company at risk of being delisted from The Nasdaq Capital Market. The company has been granted an initial 180-day compliance period, ending on August 26, 2024, to rectify the bid price deficiency. If compliance is not achieved by this deadline, 60 Degrees Pharmaceuticals may be eligible for an additional 180-day period, provided it meets certain conditions, including a potential reverse stock split. The company's common stock and warrants will continue to trade on The Nasdaq under the symbols 'SXTP' and 'SXTPW' while it evaluates options to regain compliance. There is no certainty that the company will be able to meet the Nasdaq's continued listing requirements in the future.
2024年2月27日，60度製藥公司收到納斯達克上市資格工作人員的通知，稱該公司的普通股在2024年1月11日至2024年2月27日的連續31個工作日內未達到每股1.00美元的最低收盤價。這種不遵守投標價格規則的行爲使該公司面臨從納斯達克資本市場退市的風險。該公司已獲准最初的180天合規期，該合規期將於2024年8月26日結束，以糾正投標價格的缺陷。如果在截止日期之前未達到合規要求，則60 Degrees Pharmicals可能有資格再延長180天，前提是它符合某些條件，包括潛在的反向股票拆分。該公司的普通股和認股權證將繼續在納斯達克上市，股票代碼爲 “SXTP” 和 “SXTPW”，同時評估恢復合規性的期權。目前尚不確定該公司將來能否滿足納斯達克的持續上市要求。
2024年2月27日，60度製藥公司收到納斯達克上市資格工作人員的通知，稱該公司的普通股在2024年1月11日至2024年2月27日的連續31個工作日內未達到每股1.00美元的最低收盤價。這種不遵守投標價格規則的行爲使該公司面臨從納斯達克資本市場退市的風險。該公司已獲准最初的180天合規期，該合規期將於2024年8月26日結束，以糾正投標價格的缺陷。如果在截止日期之前未達到合規要求，則60 Degrees Pharmicals可能有資格再延長180天，前提是它符合某些條件，包括潛在的反向股票拆分。該公司的普通股和認股權證將繼續在納斯達克上市，股票代碼爲 “SXTP” 和 “SXTPW”，同時評估恢復合規性的期權。目前尚不確定該公司將來能否滿足納斯達克的持續上市要求。
有用
沒用